A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.
NCT ID: NCT07280858
Last Updated: 2026-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
368 participants
INTERVENTIONAL
2026-01-28
2028-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
If the study drug has any side effects when given as single and multiple vaccinations.
If reactogenicity, an indication that the immune systems is working and is preparing to protect the body against future infection, occurs. This is a normal physical inflammatory response that occurs after vaccination, manifesting as localised reactions that may include pain or redness at the injection site, or systemic symptoms such as headache or fever.
If immunogenicity which is when GBP511 causes your body to make antibodies against the non-harmful viral proteins contained within GBP511, called 'neutralising antibodies (Nab),' occurs. And if GBP511 will cause the specialised cells of the body's immune system to mount a defence against the non-harmful viral proteins contained within GBP511, called 'cell-mediated immunity (CMI)'.
In this study, GBP511 will be administered with and without adjuvant, CAS-1. An adjuvant is an ingredient used in some vaccines that help produce a stronger immune response in the people receiving the vaccine and thus helps the vaccine work better.
This study will recruit approximately 368 participants in total and will be conducted in two stages:
Stage 1 will look at two vaccinations with GBP511 when given with and without the CAS-1 adjuvant; and Stage 2 will look at either one or two vaccinations with two candidate GBP511 vaccines chosen from Stage 1 of the study.
Participants will be required to attend Linear's clinical unit on two separate occasions to receive their two vaccinations. On the first day of dosing (Visit 2/Day 1) and second day of dosing (Visit 5/Day 29), we will be testing a single dose of the study drug in up to 168 healthy volunteers who will be divided into 3 groups. Group 1, Groups 2 and 3 will have 56 people each. These 3 groups will be divided into treatment subgroups, with a total of 6 test subgroups and 3 control subgroups. In all groups, neither you or the study doctor will know what subgroup you are part of, and therefore what treatment (GBP511 or Comirnaty+ placebo) you will receive.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
NCT05680454
Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older
NCT01165177
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
NCT03629886
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
NCT05158777
Safety Study of NBP608 in Healthy Adult Volunteers
NCT03121638
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test Group 1-1 (GBP511)
Low-dose of recombinant protein nanoparticle pan-Sarbecovirus vaccine (2µg of RBD/strain); a total injection volume of 0.5mL
IM injections on Day 1, 29 (Visit 2, 5)
Test Drug 1-1 (GBP511 low dose)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain
Test Group 1-2 (GBP511+CAS-1)
Low-dose of recombinant protein nanoparticle pan-Sarbecovirus vaccine (2µg of RBD/strain) adjuvanted with a standard dose of CAS-1; a total injection volume of 0.5mL
IM injections on Day 1, 29 (Visit 2, 5)
Test Drug 2-1 (GBP511 low dose + CAS-1)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
GBP511 - Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain CAS-1 standard adjuvant dose
Control Group
Comirnaty (2025-26 or subsequent seasonal formulation, 30 mcg of SARS-CoV-2 LP.8.1 spike protein mRNA); a total injection volume of 0.3mL Normal saline; a total injection volume of 0.5mL
Comirnaty: IM injection on Day 1 (Visit 2) Normal Saline: IM injection on Day 29 (Visit 5)
Comparator (Comirnaty)
injection volume of 0.3mililiter (mL) with single-dose at visit 2.
30 mcg of SARS-CoV-2 LP.8.1 spike protein mRNA per 0.3mL
Placebo (Normal Saline)
injection volume of 0.5mililiter (mL) with single-dose at visit 5.
Test group 1-3 (GBP511)
Mid-dose of recombinant protein nanoparticle pan-Sarbecovirus vaccine (6µg of RBD/strain); a total injection volume of 0.5mL IM injections on Day 1, 29 (Visit 2, 5)
Test Drug 1-2 (GBP511 mid dose)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain
Test group 1-4 (GBP511+CAS-1)
Mid-dose of recombinant protein nanoparticle pan-Sarbecovirus vaccine (6µg of RBD/strain) adjuvanted with a standard dose of CAS-1; a total injection volume of 0.5mL IM injections on Day 1, 29 (Visit 2, 5)
Test Drug 2-2 (GBP511 mid dose + CAS-1)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
GBP511 - Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain CAS-1 standard adjuvant dose
Test Group 1-5 (GBP511)
High-dose of recombinant protein nanoparticle pan-Sarbecovirus vaccine (18µg of RBD/strain); a total injection volume of 0.5mL IM injections on Day 1, 29 (Visit 2, 5)
Test Drug 1-3 (GBP511 high dose)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain
Test Group 1-6 (GBP511+CAS-1)
High-dose of recombinant protein nanoparticle pan-Sarbecovirus vaccine (18µg of RBD/strain) adjuvanted with a standard dose of CAS-1; a total injection volume of 0.5mL IM injections on Day 1, 29 (Visit 2, 5)
Test Drug 2-3 (GBP511 high dose + CAS-1)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
GBP511 - Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain CAS-1 standard adjuvant dose
Test Group 2-1 (Stage 2)
Participants will receive 2 intramuscular injections of the test vaccine in stage 2.
Injections on Day 1, 29 (Visit 2, 5), in line with the selected dose regimen in stage 1.
Test Drug 13 (Stage 2, GBP511-A or B)
Participants will receive 2 intramuscular injections of the test vaccine in stage 2.
Injections on Day 1, 29 (Visit 2, 5), in line with the selected dose regimen in stage 1.
Test Group 2-2 (Stage 2)
Participants will receive 2 intramuscular injections of the test vaccine in stage 2.
Injections on Day 1, 29 (Visit 2, 5), in line with the selected dose regimen in stage 1.
Test Drug 14 (Stage 2, GBP511-A or B)
Participants will receive 2 intramuscular injections of the test vaccine in stage 2.
Injections on Day 1, 29 (Visit 2, 5), in line with the selected dose regimen in stage 1.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Test Drug 1-1 (GBP511 low dose)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain
Test Drug 1-2 (GBP511 mid dose)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain
Test Drug 1-3 (GBP511 high dose)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain
Test Drug 2-1 (GBP511 low dose + CAS-1)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
GBP511 - Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain CAS-1 standard adjuvant dose
Test Drug 2-2 (GBP511 mid dose + CAS-1)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
GBP511 - Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain CAS-1 standard adjuvant dose
Test Drug 2-3 (GBP511 high dose + CAS-1)
injection volume of 0.5mililiter (mL) with 2-doses at 4 weeks interval in stage 1 and 1-dose or 2-doses at 4 weeks interval in stage 2.
GBP511 - Low dose: 2μg/strain, Mid dose: 6μg/strain, High dose: 18μg/strain CAS-1 standard adjuvant dose
Comparator (Comirnaty)
injection volume of 0.3mililiter (mL) with single-dose at visit 2.
30 mcg of SARS-CoV-2 LP.8.1 spike protein mRNA per 0.3mL
Placebo (Normal Saline)
injection volume of 0.5mililiter (mL) with single-dose at visit 5.
Test Drug 13 (Stage 2, GBP511-A or B)
Participants will receive 2 intramuscular injections of the test vaccine in stage 2.
Injections on Day 1, 29 (Visit 2, 5), in line with the selected dose regimen in stage 1.
Test Drug 14 (Stage 2, GBP511-A or B)
Participants will receive 2 intramuscular injections of the test vaccine in stage 2.
Injections on Day 1, 29 (Visit 2, 5), in line with the selected dose regimen in stage 1.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. For Stage 1, participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
For Stage 2, participant must be 18 years of age and older, at the time of signing the informed consent.
Type of Participant and Disease Characteristics
2. Participants who are healthy as determined by medical evaluation including medical history, vital signs, physical examination, clinical laboratory tests, and medical judgement of the investigator.
3. Participants who are willing and able to attend all scheduled visits and comply with all study procedures.
4. Body mass index (BMI) within the range of 18.5-32.0 kg/m2 (revised) at screening
5. Participants who received a primary series and at least one booster dose of an authorized COVID-19 vaccine at least 24 weeks prior to the 1st study vaccination.
Sex and Contraceptive/Barrier Requirements
6. All participants must agree to be abstinent from heterosexual intercourse or agree to consistently use at least one acceptable method of contraception from at least 4 weeks prior to the 1st study vaccination to 12 weeks after the last study vaccination (See Appendix 10.4 for detailed contraceptive methods).
7. Women of childbearing potential (WOCBP) with a negative urine or serum pregnancy test at screening.
\* Female participants who are surgically sterile (e.g., having undergone a full hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal with at least 12 months amenorrhoea not considered to be caused by any other medical condition, are not subject to a pregnancy test.
Informed Consent
8. Participants who are capable of giving signed informed consent as described in Appendix 10.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol before initiation of any trial-specific procedures.
Exclusion Criteria
1. Any clinically significant respiratory symptoms (e.g., cough, sore throat), febrile illness (tympanic temperature \>38°C), or acute illness within 24 hours prior to the 1st study vaccination. Prospective participants with these conditions cannot be included until 24 hours after resolution.
2. Concurrent or a history of virologically or serologically confirmed SARS-CoV-2 infection, or suspected SARS-CoV-2 infection as determined by the investigator, within 24 weeks prior to the 1st study vaccination.
3. History of virologically or serologically confirmed SARS-CoV-1, or MERS disease.
4. History of congenital, hereditary, acquired immunodeficiency, or autoimmune disease.
5. Any positive test results for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) at screening.
6. History of bleeding disorder or thrombocytopenia which is contraindicating intramuscular vaccination in the investigator's opinion.
7. History of hypersensitivity and severe allergic reaction (e.g., anaphylaxis) to any vaccines or components of the study intervention.
8. History of neurologic diseases (e.g., Guillain-Barre syndrome, myelitis, or encephalomyelitis).
9. History of myocarditis, pericarditis or myopericarditis, as assessed by the investigator, indicating probable or possible myocarditis, pericarditis, or myopericarditis, or demonstrating clinically significant abnormalities that could affect participant safety or the interpretation of study findings.
10. History of malignancy within 1 year prior to first study vaccination, except for cutaneous non-melanoma malignancy, melanoma-in-situ, or cervical carcinoma in situ that have been fully treated with completed follow-up prior to screening. Malignancy considered to carry minimal risk of recurrence may also be permitted at the discretion of the investigator.
11. Significant unstable chronic or acute illness that, in the opinion of the investigator, might pose a health risk to the participant if enrolled, or could interfere with the protocol-specified activities, or interpretation of study results.
12. Any other conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g., alcohol or drug abuse, neurologic or psychiatric conditions).
13. Female participants who are pregnant or breastfeeding.
Prior/Concomitant therapy
14. Receipt of any COVID-19 vaccination including investigational vaccines within 24 weeks prior to the 1st study vaccination or planned receipt at any time during the study period.
15. Receipt of any vaccinations intended to prevent SARS-CoV-1 or MERS, including investigational vaccines.
16. Receipt of any vaccine within 4 weeks prior to the 1st study vaccination or planned receipt of any vaccine through 4 weeks after the last study vaccination, except for influenza vaccination, which may be received at least 2 weeks prior to the 1st study vaccination.
17. Receipt of any immunoglobulins and/or blood-derived products within 12 weeks prior to the 1st study vaccination or planned receipt at any time during the study period.
18. Receipt of immunosuppressive therapy, such as any use of anti-cancer chemotherapy or radiation therapy; or chronic use of systemic corticosteroid (≥10 mg prednisone/day or equivalent more than 14 consecutive days) within 12 weeks prior to the 1st study vaccination and throughout the entire study period. The use of intranasal, inhaled, topical, or intra-articular corticosteroid is permitted.
Prior/Concurrent Clinical Study Experience
19. Participation in another clinical study and receipt of study intervention within 4 weeks prior to the 1st study vaccination, or concurrent, planned participation in another clinical study with study intervention during this study period.
Other Exclusions
20. Investigators, or study staff who are directly involved in the conduct of this study or supervised by the investigator, and their respective family members.
21. Donation of ≥450mL of blood product within 4 weeks prior to screening, or planned donation of blood product from enrollment through 12 weeks after the last study vaccination.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SK Bioscience Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Linear
Joondalup, Western Australia, Australia
Linear
Nedlands, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GBP511_001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.